Gastroparesia

Camilleri M, Kuo B, Nguyen L, et al. ACG clinical guideline: gastroparesis. Am J Gastroenterol. 2022 Aug 1;117(8):1197-220.Texto completo  Resumo

Lacy BE, Tack J, Gyawali CP. AGA clinical practice update on management of medically refractory gastroparesis: expert review. Clin Gastroenterol Hepatol. 2022 Mar;20(3):491-500.Texto completo  Resumo

Schol J, Wauters L, Dickman R, et al. United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on gastroparesis. United European Gastroenterol J. 2021 Apr;9(3):287-306.Texto completo  Resumo

1. Camilleri M, Kuo B, Nguyen L, et al. ACG clinical guideline: gastroparesis. Am J Gastroenterol. 2022 Aug 1;117(8):1197-220.Texto completo  Resumo

2. Lacy BE, Tack J, Gyawali CP. AGA clinical practice update on management of medically refractory gastroparesis: expert review. Clin Gastroenterol Hepatol. 2022 Mar;20(3):491-500.Texto completo  Resumo

3. Dong K, Yu XJ, Li B, et al. Advances in mechanisms of postsurgical gastroparesis syndrome and its diagnosis and treatment. Chin J Dig Dis. 2006;7(2):76-82. Resumo

4. Balaji NS, Crookes PF, Banki F, et al. A safe and noninvasive test for vagal integrity revisited. Arch Surg. 2002 Aug;137(8):954-8. Resumo

5. Jacob A, Pittock SJ. Gastroparesis in multiple sclerosis. Mult Scler. 2007 Jun;13(5):686. Resumo

6. Raghav S, Kipp D, Watson J, et al. Gastroparesis with multiple sclerosis. Mult Scler. 2006 Apr;12(2):243-4. Resumo

7. Moshiree B, Potter M, Talley NJ. Epidemiology and pathophysiology of gastroparesis. Gastrointest Endosc Clin N Am. 2019 Jan;29(1):1-14. Resumo

8. Jung HK, Choung RS, Locke GR 3rd, et al. The incidence, prevalence, and outcomes of patients with gastroparesis in Olmsted County, Minnesota, from 1996 to 2006. Gastroenterology. 2009 Apr;136(4):1225-33.Texto completo  Resumo

9. Ye Y, Yin Y, Huh SY, et al. Epidemiology, etiology, and treatment of gastroparesis: real-world evidence from a large US national claims database. Gastroenterology. 2022 Jan;162(1):109-21.e5.Texto completo  Resumo

10. Bytzer P, Talley NJ, Leemon M, et al. Prevalence of gastrointestinal symptoms associated with diabetes mellitus: a population-based survey of 15,000 adults. Arch Intern Med. 2001 Sep 10;161(16):1989-96. Resumo

11. Maleki D, Locke GR 3rd, Camilleri M, et al. Gastrointestinal tract symptoms among persons with diabetes mellitus in the community. Arch Intern Med. 2000 Oct 9;160(18):2808-16. Resumo

12. Jones KL, Russo A, Stevens JE, et al. Predictors of delayed gastric emptying in diabetes. Diabetes Care. 2001 Jul;24(7):1264-9. Resumo

13. Cetin K, Gungor B, Isik A, et al. The effect of pneumatic balloon dilatation on gastric emptying in patients with achalasia. Hepatogastroenterology. 2003 Dec;50(suppl 2):ccci-ii. Resumo

14. Benini L, Sembenini C, Salandini L, et al. Gastric emptying of realistic meals with and without gluten in patients with coeliac disease. Effect of jejunal mucosal recovery. Scand J Gastroenterol. 2001 Oct;36(10):1044-8. Resumo

15. Perri F, Pastore M, Zicolella A, et al. Gastric emptying of solids is delayed in celiac disease and normalizes after gluten withdrawal. Acta Paediatr. 2000 Aug;89(8):921-5. Resumo

16. Hasler WL. Gastroparesis: symptoms, evaluation, and treatment. Gastroenterol Clin North Am. 2007 Sep;36(3):619-47, ix. Resumo

17. Zipfel S, Sammet I, Rapps N, et al. Gastrointestinal disturbances in eating disorders: clinical and neurobiological aspects. Auton Neurosci. 2006 Oct 30;129(1-2):99-106. Resumo

18. Goetze O, Wieczorek J, Mueller T, et al. Impaired gastric emptying of a solid test meal in patients with Parkinson's disease using 13C-sodium octanoate breath test. Neurosci Lett. 2005 Mar 3;375(3):170-3. Resumo

19. Goetze O, Nikodem AB, Wiezcorek J, et al. Predictors of gastric emptying in Parkinson's disease. Neurogastroenterol Motil. 2006 May;18(5):369-75. Resumo

20. Soykan I, Sivri B, Sarosiek I, et al. Demography, clinical characteristics, psychological and abuse profiles, treatment, and long-term follow-up of patients with gastroparesis. Dig Dis Sci. 1998 Nov;43(11):2398-404. Resumo

21. Sjogren RW. Gastrointestinal features of scleroderma. Curr Opin Rheumatol. 1996 Nov;8(6):569-75. Resumo

22. Sridhar KR, Lange RC, Magyar L, et al. Prevalence of impaired gastric emptying of solids in systemic sclerosis: diagnostic and therapeutic implications. J Lab Clin Med. 1998 Dec;132(6):541-6. Resumo

23. Marie I, Levesque H, Ducrotte P, et al. Gastric involvement in systemic sclerosis: a prospective study. Am J Gastroenterol. 2001 Jan;96(1):77-83. Resumo

24. Shih WJ, DeLand FH, Domstad PA, et al. Scintigraphic findings in primary amyloidosis of the heart and stomach. Clin Nucl Med. 1985 Jul;10(7):466-7. Resumo

25. Jonderko G, Jonderko K, Marcisz C, et al. Evaluation of gastric emptying in patients with hypothyroidism [in Polish]. Pol Arch Med Wewn. 1996 Aug;96(2):117-23. Resumo

26. Kahraman H, Kaya N, Demircali A, et al. Gastric emptying time in patients with primary hypothyroidism. Eur J Gastroenterol Hepatol. 1997 Sep;9(9):901-4. Resumo

27. Van Vlem B, Schoonjans R, Vanholder R, et al. Dyspepsia and gastric emptying in chronic renal failure patients. Clin Nephrol. 2001 Oct;56(4):302-7. Resumo

28. Van Vlem B, Schoonjans R, Vanholder R, et al. Delayed gastric emptying in dyspeptic chronic hemodialysis patients. Am J Kidney Dis. 2000 Nov;36(5):962-8. Resumo

29. Naftali T, Yishai R, Zangen T, et al. Post-infectious gastroparesis: clinical and electrogastrographic aspects. J Gastroenterol Hepatol. 2007 Sep;22(9):1423-8. Resumo

30. Eisenberg D. Gastroparesis and herpes. Dig Dis Sci. 1988 Aug;33(8):1050. Resumo

31. Navas CM, Patel NK, Lacy BE. Gastroparesis: medical and therapeutic advances. Dig Dis Sci. 2017 Sep;62(9):2231-40. Resumo

32. Caras S, Laurie S, Cronk W, et al. Case report: pancreatic cancer presenting with paraneoplastic gastroparesis. Am J Med Sci. 1996 Jul;312(1):34-6. Resumo

33. Berghmans T, Musch W, Brenez D, et al. Paraneoplastic gastroparesis [in French]. Rev Med Brux. 1993 Nov-Dec;14(9-10):275-8. Resumo

34. Franke A, Nakchbandi IA, Schneider A, et al. The effect of ethanol and alcoholic beverages on gastric emptying of solid meals in humans. Alcohol Alcohol. 2005 May-Jun;40(3):187-93. Resumo

35. Patrick A, Epstein O. Review article: gastroparesis. Aliment Pharmacol Ther. 2008 May;27(9):724-40.Texto completo  Resumo

36. Koch KL. Diabetic gastropathy: gastric neuromuscular dysfunction in diabetes mellitus: a review of symptoms, pathophysiology, and treatment. Dig Dis Sci. 1999 Jun;44(6):1061-75. Resumo

37. Hinder RA, Kelly KA. Human gastric pacesetter potential. Site of origin, spread, and response to gastric transection and proximal gastric vagotomy. Am J Surg. 1977 Jan;133(1):29-33. Resumo

38. Camilleri M, Brown ML, Malagelada JR. Relationship between impaired gastric emptying and abnormal gastrointestinal motility. Gastroenterology. 1986 Jul;91(1):94-9. Resumo

39. Houghton LA, Read NW, Heddle R, et al. Relationship of the motor activity of the antrum, pylorus, and duodenum to gastric emptying of a solid-liquid mixed meal. Gastroenterology. 1988 Jun;94(6):1285-91. Resumo

40. Mearin F, Camilleri M, Malagelada JR. Pyloric dysfunction in diabetics with recurrent nausea and vomiting. Gastroenterology. 1986 Jun;90(6):1919-25. Resumo

41. Forster J, Damjanov I, Lin Z, et al. Absence of the interstitial cells of Cajal in patients with gastroparesis and correlation with clinical findings. J Gastrointest Surg. 2005 Jan;9(1):102-8. Resumo

42. Zarate N, Mearin F, Wang XY, et al. Severe idiopathic gastroparesis due to neuronal and interstitial cells of Cajal degeneration: pathological findings and management. Gut. 2003 Jul;52(7):966-70. Resumo

43. Hasler WL, Soudah HC, Dulai G, et al. Mediation of hyperglycemia-evoked gastric slow-wave dysrhythmias by endogenous prostaglandins. Gastroenterology. 1995 Mar;108(3):727-36. Resumo

44. Fraser RJ, Horowitz M, Maddox AF, et al. Hyperglycaemia slows gastric emptying in type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 1990 Nov;33(11):675-80. Resumo

45. Hunter RJ, Metz DC, Morris JB, et al. Gastroparesis: a potential pitfall of laparoscopic Nissen fundoplication. Am J Gastroenterol. 1996 Dec;91(12):2617-8. Resumo

46. Reddymasu SC, Bonino J, McCallum RW. Gastroparesis secondary to a demyelinating disease: a case series. BMC Gastroenterol. 2007 Jan 31;7:3. Resumo

47. Parkman, HP, Hasler WL, Fisher RS. American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology. 2004 Nov;127(5):1592-622.Texto completo  Resumo

48. Wood JD, Galligan JJ. Function of opioids in the enteric nervous system. Neurogastroenterol Motil. 2004 Oct;16(suppl 2):17-28. Resumo

49. Parkman HP, Trate DM, Knight LC, et al. Cholinergic effects on human gastric motility. Gut. 1999 Sep;45(3):346-54. Resumo

50. Foxx-Orenstein A, Camilleri M, Stephens D, et al. Effect of a somatostatin analogue on gastric motor and sensory functions in healthy humans. Gut. 2003 Nov;52(11):1555-61. Resumo

51. Tougas G, Earnest DL, Chen Y, et al. Omeprazole delays gastric emptying in healthy volunteers: an effect prevented by tegaserod. Aliment Pharmacol Ther. 2005 Jul 1;22(1):59-65. Resumo

52. Nishiguchi S, Shiomi S, Kurooka H, et al. Randomized trial assessing gastric emptying in patients with chronic hepatitis C during interferon-alpha or -beta therapy and effect of cisapride. Dig Dis Sci. 2002 Jan;47(1):73-8. Resumo

53. Hardoff R, Sula M, Tamir A, et al. Gastric emptying time and gastric motility in patients with Parkinson's disease. Mov Disord. 2001 Nov;16(6):1041-7. Resumo

54. Young A. Inhibition of gastric emptying. Adv Pharmacol. 2005;52:99-121. Resumo

55. Jonderko K, Jonderko G, Golab T. Effect of calcitonin on gastric emptying and on serum insulin and gastrin concentrations after ingestion of a mixed solid-liquid meal in humans. J Clin Gastroenterol. 1990 Feb;12(1):22-8. Resumo

56. Aring AM, Jones DE, Falko JM. Evaluation and prevention of diabetic neuropathy. Am Fam Physician. 2005 Jun 1;71(11):2123-8. Resumo

57. Evert AB, Dennison M, Gardner CD, et al. Nutrition therapy for adults with diabetes or prediabetes: a consensus report. Diabetes Care. 2019 May;42(5):731-54.Texto completo  Resumo

58. Park MI, Camilleri M. Gastroparesis: clinical update. Am J Gastroenterol. 2006 May;101(5):1129-39. Resumo

59. Coelho-Prabhu N, Forbes N, Thosani NC, et al; ASGE Standards of Practice Committee. Adverse events associated with EGD and EGD-related techniques. Gastrointest Endosc. 2022 Sep;96(3):389-401.e1.Texto completo  Resumo

60. American Diabetes Association Professional Practice Committee. 12. Retinopathy, neuropathy, and foot care: standards of care in diabetes-2024. Diabetes Care. 2024 Jan 1;47(suppl 1):S231-43.Texto completo  Resumo

61. Tougas G, Eaker EY, Abell TL, et al. Assessment of gastric emptying using a low fat meal: establishment of international control values. Am J Gastroenterol. 2000 Jun;95(6):1456-62. Resumo

62. Abell TL, Camilleri M, Donohoe K, et al. Consensus recommendations for gastric emptying scintigraphy: a joint report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. Am J Gastroenterol. 2008 Mar;103(3):753-63.Texto completo  Resumo

63. Bharucha AE, Camilleri M, Veil E, et al. Comprehensive assessment of gastric emptying with a stable isotope breath test. Neurogastroenterol Motil. 2013 Jan;25(1):e60-9.Texto completo  Resumo

64. Rao SS, Camilleri M, Hasler WL, et al. Evaluation of gastrointestinal transit in clinical practice: position paper of the American and European Neurogastroenterology and Motility Societies. Neurogastroenterol Motil. 2011 Jan;23(1):8-23.Texto completo  Resumo

65. Kuo B, McCallum RW, Koch KL, et al. Comparison of gastric emptying of a nondigestible capsule to a radio-labelled meal in healthy and gastroparetic subjects. Aliment Pharmacol Ther. 2008 Jan 15;27(2):186-96.Texto completo  Resumo

66. Lee AA, Rao S, Nguyen LA, et al. Validation of diagnostic and performance characteristics of the wireless motility capsule in patients with suspected gastroparesis. Clin Gastroenterol Hepatol. 2019 Aug;17(9):1770-9.e2.Texto completo  Resumo

67. Carson DA, O'Grady G, Du P, et al. Body surface mapping of the stomach: new directions for clinically evaluating gastric electrical activity. Neurogastroenterol Motil. 2021 Mar;33(3):e14048. Resumo

68. Schol J, Wauters L, Dickman R, et al. United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on gastroparesis. United European Gastroenterol J. 2021 Apr;9(3):287-306.Texto completo  Resumo

69. Revicki DA, Rentz AM, Dubois D, et al. Gastroparesis Cardinal Symptom Index (GCSI): development and validation of a patient reported assessment of severity of gastroparesis symptoms. Qual Life Res. 2004 May;13(4):833-44. Resumo

70. Namin F, Patel J, Lin Z, et al. Clinical, psychiatric and manometric profile of cyclic vomiting syndrome in adults and response to tricyclic therapy. Neurogastroenterol Motil. 2007 Mar;19(3):196-202. Resumo

71. Fleisher DR, Gornowicz B, Adams K, et al. Cyclic vomiting syndrome in 41 adults: the illness, the patients, and problems of management. BMC Med. 2005 Dec 21;3:20.Texto completo  Resumo

72. Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology. 2006 Apr;130(5):1377-90. Resumo

73. Koskenpato J, Kairemo K, Korppi-Tommola T, et al. Role of gastric emptying in functional dyspepsia: a scintigraphic study of 94 subjects. Dig Dis Sci. 1998 Jun;43(6):1154-8. Resumo

74. Soykan I, Chen J, Kendall BJ, et al. The rumination syndrome: clinical and manometric profile, therapy, and long-term outcome. Dig Dis Sci. 1997 Sep;42(9):1866-72. Resumo

75. O'Brien MD, Bruce BK, Camilleri M. The rumination syndrome: clinical features rather than manometric diagnosis. Gastroenterology. 1995 Apr;108(4):1024-9. Resumo

76. Chaum M, Shouhed D, Kim S, et al. Clinico-pathologic findings in patients with median arcuate ligament syndrome (celiac artery compression syndrome). Ann Diagn Pathol. 2021 Jun;52:151732. Resumo

77. Warncke ES, Gursahaney DL, Mascolo M, et al. Superior mesenteric artery syndrome: a radiographic review. Abdom Radiol (NY). 2019 Sep;44(9):3188-94. Resumo

78. Downes TJ, Cheruvu MS, Karunaratne TB, et al. Pathophysiology, diagnosis, and management of chronic intestinal pseudo-obstruction. J Clin Gastroenterol. 2018 Jul;52(6):477-89. Resumo

79. Sorensen CJ, DeSanto K, Borgelt L, et al. Cannabinoid hyperemesis syndrome: diagnosis, pathophysiology, and treatment - a systematic review. J Med Toxicol. 2017 Mar;13(1):71-87.Texto completo  Resumo

80. Olausson EA, Störsrud S, Grundin H, et al. A small particle size diet reduces upper gastrointestinal symptoms in patients with diabetic gastroparesis: a randomized controlled trial. Am J Gastroenterol. 2014 Mar;109(3):375-85. Resumo

81. Abell TL, Bernstein RK, Cutts T, et al. Treatment of gastroparesis: a multidisciplinary clinical review. Neurogastroenterol Motil. 2006 Apr;18(4):263-83. Resumo

82. McCallum RW, Ricci DA, Rakatansky H, et al. A multicenter placebo-controlled clinical trial of oral metoclopramide in diabetic gastroparesis. Diabetes Care. 1983 Sep-Oct;6(5):463-7. Resumo

83. Ricci DA, Saltzman MB, Meyer C, et al. Effect of metoclopramide in diabetic gastroparesis. J Clin Gastroenterol. 1985 Feb;7(1):25-32. Resumo

84. European Medicines Agency. European Medicines Agency recommends changes to the use of metoclopramide. Jul 2013 [internet publication].Texto completo

85. Zheng T, Camilleri M. Management of gastroparesis. Gastroenterol Hepatol (N Y). 2021 Nov;17(11):515-25.Texto completo  Resumo

86. Ganzini L, Casey DE, Hoffman WF, et al. The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders. Arch Intern Med. 1993 Jun 28;153(12):1469-75. Resumo

87. Shaffer D, Butterfield M, Pamer C, et al. Tardive dyskinesia risks and metoclopramide use before and after U.S. market withdrawal of cisapride. J Am Pharm Assoc (2003). 2004 Nov-Dec;44(6):661-5. Resumo

88. Cavero-Redondo I, Álvarez-Bueno C, Pozuelo-Carrascosa DP, et al. Risk of extrapyramidal side effects comparing continuous vs. bolus intravenous metoclopramide administration: a systematic review and meta-analysis of randomised controlled trials. J Clin Nurs. 2015 Dec;24(23-24):3638-46. Resumo

89. European Medicines Agency. CMDh confirms recommendations on restricting use of domperidone-containing medicines. Apr 2014 [internet publication].Texto completo

90. Stewart JJ, Wood MJ, Wood CD, et al. Effects of motion sickness and antimotion sickness drugs on gastric function. J Clin Pharmacol. 1994 Jun;34(6):635-43. Resumo

91. Sawhney MS, Prakash C, Lustman PJ, et al. Tricyclic antidepressants for chronic vomiting in diabetic patients. Dig Dis Sci. 2007 Feb;52(2):418-24. Resumo

92. Parkman HP, Van Natta ML, Abell TL, et al. Effect of nortriptyline on symptoms of idiopathic gastroparesis: the NORIG randomized clinical trial. JAMA. 2013 Dec 25;310(24):2640-9.Texto completo  Resumo

93. Malamood M, Roberts A, Kataria R, et al. Mirtazapine for symptom control in refractory gastroparesis. Drug Des Devel Ther. 2017 Mar 30;11:1035-41.Texto completo  Resumo

94. Camilleri M, Sanders KM. Opiates, the pylorus, and gastroparesis. Gastroenterology. 2020 Aug;159(2):414-21.Texto completo  Resumo

95. Kim KH, Lee MS, Choi TY, et al. Acupuncture for symptomatic gastroparesis. Cochrane Database Syst Rev. 2018 Dec 18;12(12):CD009676.Texto completo  Resumo

96. Lin Z, McElhinney C, Sarosiek I, et al. Chronic gastric electrical stimulation for gastroparesis reduces the use of prokinetic and/or antiemetic medications and the need for hospitalizations. Dig Dis Sci. 2005 Jul;50(7):1328-34. Resumo

97. Cutts TF, Luo J, Starkebaum W, et al. Is gastric electrical stimulation superior to standard pharmacologic therapy in improving GI symptoms, healthcare resources, and long-term health care benefits? Neurogastroenterol Motil. 2005 Feb;17(1):35-43. Resumo

98. O'Grady G, Egbuji JU, Du P, et al. High-frequency gastric electrical stimulation for the treatment of gastroparesis: a meta-analysis. World J Surg. 2009 Aug;33(8):1693-701.Texto completo  Resumo

99. National Institute for Health and Care Excellence. Gastroelectrical stimulation for gastroparesis. May 2014 [internet publication].Texto completo

100. Jones MP, Maganti K. A systematic review of surgical therapy for gastroparesis. Am J Gastroenterol. 2003 Oct;98(10):2122-9. Resumo

101. Khashab MA, Wang AY, Cai Q. AGA Clinical practice update on gastric peroral endoscopic myotomy for gastroparesis: commentary. Gastroenterology. 2023 Jun;164(7):1329-35.e1.Texto completo  Resumo

102. Jehangir A, Malik Z, Petrov RV, et al. EndoFLIP and pyloric dilation for gastroparesis symptoms refractory to pyloromyotomy/pyloroplasty. Dig Dis Sci. 2021 Aug;66(8):2682-90. Resumo

103. Bromer MQ, Friedenberg F, Miller LS, et al. Endoscopic pyloric injection of botulinum toxin A for the treatment of refractory gastroparesis. Gastrointest Endosc. 2005 Jun;61(7):833-9. Resumo

104. Arts J, van Gool S, Caenepeel P, et al. Influence of intrapyloric botulinum toxin injection on gastric emptying and meal-related symptoms in gastroparesis patients. Aliment Pharmacol Ther. 2006 Aug 15;24(4):661-7. Resumo

105. Bai Y, Xu MJ, Yang X, et al. A systematic review on intrapyloric botulinum toxin injection for gastroparesis. Digestion. 2010;81(1):27-34. Resumo

106. Kuo B, Barnes CN, Nguyen DD, et al. Velusetrag accelerates gastric emptying in subjects with gastroparesis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 study. Aliment Pharmacol Ther. 2021 May;53(10):1090-7. Resumo

107. Chedid V, Brandler J, Arndt K, et al. Randomised study: effects of the 5-HT(4) receptor agonist felcisetrag vs placebo on gut transit in patients with gastroparesis. Aliment Pharmacol Ther. 2021 May;53(9):1010-20.Texto completo  Resumo

108. Andrews CN, Woo M, Buresi M, et al. Prucalopride in diabetic and connective tissue disease-related gastroparesis: randomized placebo-controlled crossover pilot trial. Neurogastroenterol Motil. 2021 Jan;33(1):e13958. Resumo

109. Carbone F, Van den Houte K, Clevers E, et al. Prucalopride in gastroparesis: a randomized placebo-controlled crossover study. Am J Gastroenterol. 2019 Aug;114(8):1265-74. Resumo

110. Lasseter KC, Shaughnessy L, Cummings D, et al. Ghrelin agonist (TZP-101): safety, pharmacokinetics and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study. J Clin Pharmacol. 2008 Feb;48(2):193-202. Resumo

111. Ejskjaer N, Dimcevski G, Wo J, et al. Safety and efficacy of ghrelin agonist TZP-101 in relieving symptoms in patients with diabetic gastroparesis: a randomized, placebo-controlled study. Neurogastroenterol Motil. 2010 Oct;22(10):1069-e281. Resumo

112. Shin A, Camilleri M, Busciglio I, et al. Randomized controlled phase Ib study of ghrelin agonist, RM-131, in type 2 diabetic women with delayed gastric emptying: pharmacokinetics and pharmacodynamics. Diabetes Care. 2013 Jan;36(1):41-8.Texto completo  Resumo

113. McCallum RW, Lembo A, Esfandyari T, et al; TZP-102 Phase 2b Study Group. Phase 2b, randomized, double-blind 12-week studies of TZP-102, a ghrelin receptor agonist for diabetic gastroparesis. Neurogastroenterol Motil. 2013 Nov;25(11):e705-17.Texto completo  Resumo

114. Lembo A, Camilleri M, McCallum R, et al; RM-131-004 Trial Group. Relamorelin reduces vomiting frequency and severity and accelerates gastric emptying in adults with diabetic gastroparesis. Gastroenterology. 2016 Jul;151(1):87-96.e6.Texto completo  Resumo

115. Ejskjaer N, Wo JM, Esfandyari T, et al. A phase 2a, randomized, double-blind 28-day study of TZP-102 a ghrelin receptor agonist for diabetic gastroparesis. Neurogastroenterol Motil. 2013 Feb;25(2):e140-50. Resumo

116. Camilleri M, McCallum RW, Tack J, et al. Efficacy and safety of relamorelin in diabetics with symptoms of gastroparesis: a randomized, placebo-controlled study. Gastroenterology. 2017 Nov;153(5):1240-50;e2.Texto completo  Resumo

117. Hong SW, Chun J, Kim J, et al. Efficacy and safety of ghrelin agonists in patients with diabetic gastroparesis: a systematic review and meta-analysis. Gut Liver. 2020 Sep 15;14(5):589-600.Texto completo  Resumo

118. Abell TL, Garcia LM, Wiener GJ, et al. Effect of oral CNSA-001 (sepiapterin, PTC923) on gastric accommodation in women with diabetic gastroparesis: a randomized, placebo-controlled, phase 2 trial. J Diabetes Complications. 2021 Sep;35(9):107961.Texto completo  Resumo

119. Kuo B, Scimia C, Dukes G, et al. Randomised clinical trial: safety, pharmacokinetics and pharmacodynamics of trazpiroben (TAK-906), a dopamine D(2)/D(3) receptor antagonist, in patients with gastroparesis. Aliment Pharmacol Ther. 2021 Aug;54(3):267-80.Texto completo  Resumo

120. Yamaguchi T, Kudou K, Okamoto H, et al. Evaluating the safety, tolerability, and disposition of trazpiroben, a D(2)/D(3) receptor antagonist: phase I single- and multiple-ascending dose studies in healthy Japanese participants. Clin Pharmacol Drug Dev. 2022 Jun;11(6):695-706.Texto completo  Resumo

121. Whiting RL, Darpo B, Chen C, et al. Safety, pharmacokinetics, and pharmacodynamics of trazpiroben (TAK-906), a novel selective D(2)/D(3) receptor antagonist: a phase 1 randomized, placebo-controlled single- and multiple-dose escalation study in healthy participants. Clin Pharmacol Drug Dev. 2021 Aug;10(8):927-39.Texto completo  Resumo

122. Tack J. Gastric motor disorders. Best Pract Res Clin Gastroenterol. 2007;21(4):633-44. Resumo

123. Lacy BE, Weiser K. Gastrointestinal motility disorders: an update. Dig Dis. 2006;24(3-4):228-42. Resumo

124. Thorn AR. Not just another case of nausea and vomiting: a review of postinfectious gastroparesis. J Am Acad Nurse Pract. 2010 Mar;22(3):125-33. Resumo

125. Soffer E, Abell T, Lin Z, et al. Review article: gastric electrical stimulation for gastroparesis - physiological foundations, technical aspects and clinical implications. Aliment Pharmacol Ther. 2009 Oct;30(7):681-94. Resumo